September 6th 2024
"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.
Robotic, open radical prostatectomy outcomes comparable in high-risk prostate cancer patients
May 22nd 2013Robot-assisted laparoscopic prostatectomy in patients with intermediate- or high-risk cancers achieves outcomes similar to those seen with the open procedure, say researchers from Vanderbilt University, Nashville, TN.
Secondary radiation therapy does not negatively impact continence
May 22nd 2013The clinical advantages of adjuvant or salvage radiation therapy in patients treated for prostate cancer by radical prostatectomy is currently a much-debated issue and is frequently decided for the individual patient. New evidence, however, seems to indicate that secondary radiation therapy (RT) does not negatively affect urinary continence.
Genetic test predicts prostate cancer recurrence
May 20th 2013A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.
AUA 2013: AUA guide takes tailored approach to PCa screening
May 4th 2013The AUA has released a PSA-focused, evidence-based guideline on early detection of prostate cancer that is intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening, said H. Ballentine Carter, MD.
Anterior sampling may be safe alternative for prostate biopsy
April 23rd 2013Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.
Prostate cancer active surveillance criteria may need to be stratified by race
April 23rd 2013African-American men eligible for active surveillance have a higher risk of advanced cancer on final surgical pathology compared to Caucasian men, suggesting the need for more stringent criteria for active surveillance for African-American men, according to a recently published study.
FDA accepts HIFU maker’s pre-market application
April 22nd 2013EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.
PSA screening cuts prostate cancer deaths by 32%, ERSPC data indicate
April 19th 2013New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
Diabetes, prostate cancer link: Surprising, or not?
April 17th 2013Men with abnormal findings on digital rectal exam or other indicators of prostate cancer should be tested, but the evidence is insufficient to justify preferentially screening diabetic men because they may be at a higher risk of developing clinically significant prostate cancer.
5-ARI does not affect prostate cancer mortality
April 2nd 2013Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.